Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152

Pragya D. Yadav, Rima R Sahay, Gajanan Sapkal, Dimpal Nyayanit, Anita M. Shete, Gururaj Deshpande, Deepak Y. Patil, Nivedita Gupta, Sanjay Kumar, Priya Abraham, Samiran Panda, Balram Bhargava
doi: https://doi.org/10.1101/2021.07.30.454511
Pragya D. Yadav
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hellopragya22@gmail.com
Rima R Sahay
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gajanan Sapkal
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimpal Nyayanit
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita M. Shete
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gururaj Deshpande
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepak Y. Patil
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nivedita Gupta
2Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, India Pin-110029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Kumar
3Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College, Pune, Maharashtra, India - 411040
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priya Abraham
1Indian Council of Medical Research-National Institute of Virology, Pune, Maharashtra, India, Pin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samiran Panda
2Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, India Pin-110029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balram Bhargava
2Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, India Pin-110029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

The recent emergence of the SARS-CoV-2 Variant of Concern, B.1.617.2 (Delta) variant and its high transmissibility has led to the second wave in India. BBV152, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in India, showed a 65.2% protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial. Subsequently, Delta has been further mutated to Delta AY.1, AY.2, and AY.3. Of these, AY.1 variant was first detected in India in April 2021 and subsequently from twenty other countries as well. Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of COVID-19 naive individual’s full doses of BBV152 vaccine, COVID-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3. A reduction in neutralizing activity was observed with the COVID-19 naive individuals full vaccinated (1.3, 1.5, 1.9-fold), COVID-19 recovered cases with full BBV152 immunization (2.5, 3.5, 3.8-fold) and breakthrough cases post-immunization (1.9, 2.8, 3.5-fold) against Delta, Delta AY.1 and B.1.617.3 respectively compared to B.1 variant. A minor reduction was observed in the neutralizing antibody titer in COVID-19 recovered cases full BBV152 vaccinated and post immunized infected cases compared to COVID-19 naive vaccinated individuals. However, with the observed high titers, the sera of individuals belonging to all the aforementioned groups they would still neutralize the Delta, Delta AY.1 and B.1.617.3 variants effectively.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 01, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152
Pragya D. Yadav, Rima R Sahay, Gajanan Sapkal, Dimpal Nyayanit, Anita M. Shete, Gururaj Deshpande, Deepak Y. Patil, Nivedita Gupta, Sanjay Kumar, Priya Abraham, Samiran Panda, Balram Bhargava
bioRxiv 2021.07.30.454511; doi: https://doi.org/10.1101/2021.07.30.454511
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152
Pragya D. Yadav, Rima R Sahay, Gajanan Sapkal, Dimpal Nyayanit, Anita M. Shete, Gururaj Deshpande, Deepak Y. Patil, Nivedita Gupta, Sanjay Kumar, Priya Abraham, Samiran Panda, Balram Bhargava
bioRxiv 2021.07.30.454511; doi: https://doi.org/10.1101/2021.07.30.454511

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Molecular Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4372)
  • Biochemistry (9561)
  • Bioengineering (7075)
  • Bioinformatics (24800)
  • Biophysics (12581)
  • Cancer Biology (9929)
  • Cell Biology (14306)
  • Clinical Trials (138)
  • Developmental Biology (7935)
  • Ecology (12085)
  • Epidemiology (2067)
  • Evolutionary Biology (15965)
  • Genetics (10910)
  • Genomics (14716)
  • Immunology (9850)
  • Microbiology (23596)
  • Molecular Biology (9463)
  • Neuroscience (50750)
  • Paleontology (369)
  • Pathology (1537)
  • Pharmacology and Toxicology (2675)
  • Physiology (4003)
  • Plant Biology (8646)
  • Scientific Communication and Education (1506)
  • Synthetic Biology (2388)
  • Systems Biology (6417)
  • Zoology (1345)